The Europe market for cardiac assist devices market is estimated at USD 505.59 Million in 2019 and is poised to reach USD 767.98 Million by 2024, growing at a CAGR of 8.72% by 2024 during the forecast period 2019-2024.
Diseases of the heart and circulatory system (cardiovascular disease or CVD) are the main cause of death in Europe: accounting for over 4 million deaths each year. Nearly half (47%) of all deaths are from CVD (52% of deaths in women and 42% of deaths in men). The main forms of CVD are coronary heart disease (CHD) and stroke
To meet the increasing demand for cardiac therapies in the European countries, the Cardiac Assist Devices (CAD) are used in patients suffering from End-Stage Congestive Heart Failure, where the chances of survival through medications alone are minimal. These devices are used as a Bridge-To-Transplantation (BTT), Bridge-To-Recovery (BTR) or Destination Therapy (DT), depending on the requirement of the patient and the severity of the disease. The upsurge in the aging population in developed countries along with the scarcity of donor organs has also added to the growing need for the development of these devices. Various pipeline products are going through clinical trials and the approval of this novel technologically advanced products that are more efficient and minimally invasive will further increase the demand for cardiac assist devices in the future.
Existence of alternative treatment like a pacemaker, heart transplantation and etc. and the associated compatibility issues with device implantation, such as respiratory failure, development of blood clots and device failure restrain the market growth. Adding to these, surgical impediments such as kidney failure, bleeding, Infection and occurrence of stroke are also acting as a barrier in the adoption of such devices.
Europe Cardiac Assist Devices Market segmented and sub-segmented into the following categories:
By Type: Ventricular Assist Devices (VAD) (Right Ventricular Assist Device (RVAD), Left Ventricular Assist Device (LVAD), Bi-Ventricular Assist Device (Bi-VAD) & External Ventricular Assist Devices), Intra-Aortic Balloon Pumps (IABP) & Total Artificial Heart (TAH).
By Country: France, Italy, Germany, Spain, the UK and Rest of Europe.
The Europe region accounts to about 16% of the Global Cardiac Assist Devices Market
Top companies in the Europe Cardiac Assist Devices Market:
Thoratec Corporation, MAQUET GmbH & Co, Teleflex Incorporated, Berlin Heart GmbH, Abiomed, Inc., HeartWare International, SynCardia Systems, Inc., Jarvik Heart, Inc., and Terumo Corporation. Braile Biomedica Ltd., CardiacAssist, Inc., CardioBridge GmbH, Carmat SAS, Cleveland Heart, Inc., CorAssist Cardiovascular Ltd., Evaheart Medical USA, Inc., Leviticus Cardio Ltd., MyoCardioCare, Inc are the leading market players with dominance over 60% of the market.
Thoratec Corporation and Berlin Heart are the prominent players in the VAD segment whereas Teleflex and MAQUET are dominant players in the Intra-Aortic Balloon Pumps (IABP) segment. SynCardia is the foremost company to provide the only Food and Drug Administration (FDA) approved Total Artificial Heart (TAH).
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2.2 Analysis Design
2.3 Research Phases
2.3.1 Secondary Research
2.3.2 Primary Research
2.3.3 Econometric Modelling
2.3.4 Expert Validation
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5.1 Global Cardiac Assist Devices Market, by Type
5.1.1 Ventricular Assist Devices (VAD)
126.96.36.199 Right Ventricular Assist Device (RVAD
188.8.131.52 Left Ventricular Assist Device (LVAD)
184.108.40.206 Bi-Ventricular Assist Device (Bi-VAD
220.127.116.11 External Ventricular Assist Devices
5.1.2 Intra-Aortic Balloon Pumps (IABP)
5.1.3 Total Artificial Heart (TAH)
7.1 PESTLE analysis
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.1 Thoratec Corporation
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Berlin Heart GmbH
8.3 Abiomed, Inc
8.4 HeartWare International
8.5 Jarvik Heart, Inc
8.6 Terumo Corporation
8.7 Calon Cardio-Technology Ltd.
8.8 CardiacAssist, Inc.
8.9 CardioBridge GmbH
8.10 Carmat SAS
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.1 Market Outlook
10.2 Investment Opportunities